FDA Reviewers Say Vorapaxar Approvable, But Question Study Changes
This article was originally published in The Pink Sheet Daily
As the platelet inhibitor heads to an advisory committee, agency reviewers raise issues about safety-based changes to its Phase III trials.
You may also be interested in...
FDA approves antiplatelet inhibitor with a label that makes little mention of the safety concerns seen in lightweight patients, despite a vibrant FDA and advisory panel discussion on how to present the unfavorable data, but the company still has a big marketing challenge ahead.
Cardio-renal advisory committee recommends against rivaroxaban’s approval for acute coronary syndromes and says exploratory analyses on duration of use could be used to design a new study. Panelists also had some thoughts on whether, and how, to study anticoagulants for acute treatment and chronic use together.
FDA’s Cardiovascular and Renal Drugs Advisory Committee says that TRA2P trial’s interim analysis issues did not affect interpretation of its results.